At present, Csnk1a1 has become a potential therapeutic target in many tumours, including chronic lymphocytic leukaemia,21 acute myeloid leukaemia 20 and multiple myeloma.22, 23. This evidence concerns the gene CSNK1A1 and acute myeloid leukemia.